Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rolditamig deuderuxtecan - Chia Tai Tianqing Pharmaceutical Group

Next Previous
Drug Profile

Rolditamig deuderuxtecan - Chia Tai Tianqing Pharmaceutical Group

Alternative Names: HER2 dual-antibody-drug conjugate - Chia Tai Tianqing Pharmaceutical Group; TQB-2102

Latest Information Update: 06 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chia Tai Tianqing Pharmaceutical Group
  • Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HER2 negative breast cancer; HER2 positive breast cancer
  • Phase II Adenocarcinoma; Gynaecological cancer; Non-small cell lung cancer
  • Phase I/II Biliary cancer; Solid tumours

Most Recent Events

  • 31 Aug 2026 Rolditamig deuderuxtecan licensed to Cipla in India, South Africa and 5 other emerging markets
  • 27 May 2026 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Combination therapy) in China (IV) (NCT07512583)
  • 28 Apr 2026 No recent reports of development identified for phase-I development in Cancer(Late-stage disease) in China (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top